oncology

News in brief: PPIs may impair efficacy of checkpoint inhibitors; Action needed on adjuvant bisphosponates in EBC; Transparency register to reveal surgeon outcomes

PPIs may impair efficacy of checkpoint inhibitors Proton pump inhibitors (PPIs) may reduce the effectiveness of some immune checkpoint inhibitors (ICI) by causing gut dysbiosis, Australian researchers say. A retrospective review of outcomes for 1202 lung cancer participants in the IMPower150 trial of immunotherapies found that PPI use was independently associated with worse Overall Survival ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic